Truxima

Biological Teva Pharmaceuticals USA, Inc.
Total Payments
$92,119
Transactions
1,046
Doctors
716
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2024 $76,434 293 261
2023 $5,664 323 261
2022 $956.31 51 44
2021 $2,176 129 96
2020 $6,888 250 167

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $71,323 1 77.4%
Food and Beverage $18,466 1,044 20.0%
Consulting Fee $2,330 1 2.5%

Payments by Type

Research
$71,323
1 transactions
General
$20,796
1,045 transactions

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
Randomized phase II trial of rituximab with either pentostatin or bendamustine for multiply relapsed or refractory hairy cell leukemia Teva Pharmaceuticals USA, Inc. $71,323 0

Top Doctors Receiving Payments for Truxima — Page 6

Doctor Specialty Location Total Records
, CRNP Nurse Practitioner Phoenix, AZ $35.17 2
, PA Physician Assistant Shreveport, LA $35.15 2
, MD Medical Oncology Dallas, TX $35.01 2
, APRN, FNP-C Family Shreveport, LA $34.96 2
Pawan Gundavaram Hematology & Oncology Roselle, NJ $34.83 3
Jonathan Lu Hematology & Oncology Kingwood, TX $34.60 2
, MB.CHB., FRCPC RHEUM Rheumatology Palm Harbor, FL $34.59 2
, M.D Rheumatology Palm Harbor, FL $34.59 2
, PA-C Physician Assistant Glendale, AZ $34.37 2
, MD Rheumatology Shreveport, LA $34.06 2
, MD Rheumatology Pembroke Pines, FL $34.02 2
, MD Specialist Las Vegas, NV $33.86 2
, D.O Rheumatology El Paso, TX $33.18 2
, M.D Hematology & Oncology San Antonio, TX $33.15 2
, APRN Nurse Practitioner Joplin, MO $33.12 2
Chelsea Bullock Family Corinth, MS $32.58 1
, PA-C Medical Gilbert, AZ $32.53 2
, NP-C Adult Health Kingwood, TX $32.16 2
, PA-C Physician Assistant Tucson, AZ $31.99 2
, M.D Rheumatology Tucson, AZ $31.99 2
, FNP Family Hattiesburg, MS $31.91 2
, PA-C Medical Peoria, AZ $31.86 2
Miranda Isom Physician Assistant Phoenix, AZ $31.85 2
, MD Internal Medicine Knoxville, TN $31.83 2
, M.D Rheumatology Knoxville, TN $31.82 2

About Truxima

Truxima is a biological associated with $92,119 in payments to 716 healthcare providers, recorded across 1,046 transactions in the CMS Open Payments database. The primary manufacturer is Teva Pharmaceuticals USA, Inc..

Payment data is available from 2020 to 2024. In 2024, $76,434 was paid across 293 transactions to 261 doctors.

The most common payment nature for Truxima is "Unspecified" ($71,323, 77.4% of total).

Truxima is associated with 1 research study, including "Randomized phase II trial of rituximab with either pentostatin or bendamustine for multiply relapsed or refractory hairy cell leukemia" ($71,323).